NextCure Q3 2026 Report: Cash Decline, R&D Cut, Merger Push & Shareholder Vote
NextCure’s Q3 2026 report shows strategic R&D cuts, a cash dip, and a merger push with Avere Therapeutics—key moves shaping future growth and shareholder value.
2 minutes to read
